Vanja Vaccaro

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment.

Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment.

Journal: Cancer medicine

Published: January 24, 2024

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.

Journal: Cancer medicine

Published: February 23, 2023

Management of maxillary artery pseudoaneurysm in Emergency Department: a narrative review.

Management of maxillary artery pseudoaneurysm in Emergency Department: a narrative review.

Journal: La Clinica terapeutica

Published: September 26, 2022

Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.

Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.

Journal: Neuroendocrinology

Published: February 08, 2022

Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study).

Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study).

Journal: Current oncology (Toronto, Ont.)

Published: April 08, 2021

Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology.

Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology.

Journal: International journal of molecular sciences

Published: October 27, 2020

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.

Journal: Therapeutic advances in medical oncology

Published: August 05, 2020

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study.

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study.

Journal: Immunotherapy

Published: February 25, 2020

From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer.

From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer.

Journal: Cells

Published: December 19, 2019

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Journal: Immunotherapy

Published: October 18, 2018

Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.

Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.

Journal: Cancer chemotherapy and pharmacology

Published: September 08, 2015

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Journal: PloS one

Published: April 20, 2015

Showing 1-12 of 21

Last Updated: 09/26/2026